Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076232 · ClinicalTrials.gov registry record · Phase 3
A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 3,682
- Enrollment target
NCT00076232 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 3,682 participants.
The verdict
NCT00076232, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,682 participants
- Enrollment target
Study Summary
Genital herpes (HSV-2) is the most common cause of genital sores worldwide, and the presence of genital sores is a significant risk factor for becoming infected with HIV. This study will test the effectiveness of twice-daily dosing of acyclovir, a commonly prescribed anti-herpes drug, in preventing HIV infection in HSV-2 infected women who sleep with men (WSM) and men who sleep with men (MSM). Study hypothesis: Given that genital herpes is a significant risk factor to HIV acquisition, twice-daily HSV-2 suppressive therapy - 400 mg of acyclovir - will prevent HIV infection among high risk, HSV-2 seropositive WSM and MSM.
Interventions
- DRUG Acyclovir
- DRUG Acyclovir placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,682 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00076232
The ClinicalTrials.gov registry entry for NCT00076232 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,682 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Acyclovir is the first listed.
NCT00076232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00076232 about?
NCT00076232 is a clinical study titled "A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes". Genital herpes (HSV-2) is the most common cause of genital sores worldwide, and the presence of genital sores is a significant risk factor for becoming infected with HIV. This study will test the effectiveness of twice-daily dosing of acyclovir, a commonly prescribed anti-herpes drug, in preventing ...
What is the current status of trial NCT00076232?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,682 participants. The study started on 2005-04. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00076232?
The interventions under investigation include: Acyclovir (DRUG), Acyclovir placebo (DRUG).
Who is sponsoring clinical trial NCT00076232?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.